Who Owns Exelixis Stock?
NASDAQ: EXELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 106.73%
- Institutions (% of float)
- 108.73%
- Held by insiders
- 1.84%
- Institutional holders
- 990
- Institutions 98.2%
- Insiders 1.8%
- Public and other 0.0%
Who owns Exelixis stock?
Institutional investors own about 106.7% of Exelixis's shares, spread across 990 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 1.84% of EXEL.
The largest institutional holders are Blackrock Inc. (11.73%), Farallon Capital Management LLC (5.44%) and Renaissance Technologies, LLC (5.42%). Together, the top 10 institutions control 50.3% of shares outstanding. In their latest filings, 3 of the top 10 institutions increased their EXEL positions and 7 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of EXEL
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 29.08M | 11.73% | -5.7% |
| Farallon Capital Management LLC | 13.47M | 5.44% | +2.7% |
| Renaissance Technologies, LLC | 13.43M | 5.42% | -2.2% |
| Vanguard Portfolio Management LLC | 12.04M | 4.86% | -0.3% |
| AQR Capital Management, LLC | 11.02M | 4.45% | -15.8% |
| Vanguard Capital Management LLC | 10.95M | 4.42% | -2.7% |
| State Street Corporation | 9.97M | 4.02% | -3.2% |
| Fuller & Thaler Asset Management Inc. | 8.93M | 3.60% | +4.5% |
| LSV Asset Management | 8.15M | 3.29% | +5.2% |
| Geode Capital Management, LLC | 7.65M | 3.09% | -1.9% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of EXEL
| Fund | Shares | % Held |
|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 8.80M | 3.55% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 7.58M | 3.06% |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund | 7.04M | 2.84% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 5.47M | 2.21% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 3.16M | 1.27% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 2.88M | 1.16% |
| Invesco Exchange-Traded Fund Trust-Invesco S&P MidCap Quality ETF | 2.78M | 1.12% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.99M | 0.80% |
| SPDR S&P MIDCAP 400 ETF TRT-State Street SPDR S&P Mid Cap 400 ETF TRT | 1.84M | 0.74% |
| iShares Trust-iShares Biotechnology ETF | 1.82M | 0.74% |
Frequently asked questions
Who is the largest shareholder of Exelixis?
Blackrock Inc. is the largest institutional shareholder of EXEL, owning 11.73% of shares outstanding (29.08M shares) as of its latest 13F filing.
What percentage of Exelixis is owned by institutions?
Institutions own about 106.7% of EXEL shares and 108.7% of the public float.
How much of Exelixis do insiders own?
Insiders, such as officers and directors, own about 1.84% of EXEL shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.